267 related articles for article (PubMed ID: 32405693)
1. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
2. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
Bendjelid K; Giraud R; Von Düring S
Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550
[No Abstract] [Full Text] [Related]
3. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Wiesmann T; Vogelmeier CF; Mack E; Skevaki C; Gaik C; Keller C; Figiel J; Sohlbach K; Rolfes C; Renz H; Wulf H; Burchert A
Leukemia; 2020 Aug; 34(8):2276-2278. PubMed ID: 32555296
[No Abstract] [Full Text] [Related]
4. COVID-19-related Acute Respiratory Distress Syndrome: Not So Atypical.
Bos LDJ
Am J Respir Crit Care Med; 2020 Aug; 202(4):622-624. PubMed ID: 32579026
[No Abstract] [Full Text] [Related]
5. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Cadegiani FA
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
[No Abstract] [Full Text] [Related]
6. [Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome].
Pan C; Xie JF; Qiu HB; Yang Y
Zhonghua Shao Shang Za Zhi; 2020 May; 36(5):330-333. PubMed ID: 32456368
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Foss FM; Rubinowitz A; Landry ML; Isufi I; Gowda L; Seropian S; Perreault S; Shenoi SV
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):720-723. PubMed ID: 32727701
[TBL] [Abstract][Full Text] [Related]
8. Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic Shock.
Wang H; Das S; Wieruszewski PM; Taji J; Bartlett B; Azad N; Chowdhury A; Kolar GJ; Jain N; Subla MR; Khan SA
Chest; 2020 Aug; 158(2):e55-e58. PubMed ID: 32335068
[TBL] [Abstract][Full Text] [Related]
9. Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia.
Phillips L; Pavisic J; Kaur D; Dorrello NV; Broglie L; Hijiya N
Blood Adv; 2020 Sep; 4(18):4358-4361. PubMed ID: 32926122
[TBL] [Abstract][Full Text] [Related]
10. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Peterson D; Damsky W; King B
J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797
[No Abstract] [Full Text] [Related]
11. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
12. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).
Altschuler EL; Kast RE
Med Hypotheses; 2020 Aug; 141():109774. PubMed ID: 32344275
[No Abstract] [Full Text] [Related]
13. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS.
Gibson PG; Qin L; Puah SH
Med J Aust; 2020 Jul; 213(2):54-56.e1. PubMed ID: 32572965
[No Abstract] [Full Text] [Related]
14. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
16. P-selectin blockade in COVID-19-related ARDS.
Neri T; Nieri D; Celi A
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1237-L1238. PubMed ID: 32464083
[No Abstract] [Full Text] [Related]
17. Considerations for Statin Therapy in Patients with COVID-19.
Dashti-Khavidaki S; Khalili H
Pharmacotherapy; 2020 May; 40(5):484-486. PubMed ID: 32267560
[No Abstract] [Full Text] [Related]
18. Colchicine may not be effective in COVID-19 infection; it may even be harmful?
Cumhur Cure M; Kucuk A; Cure E
Clin Rheumatol; 2020 Jul; 39(7):2101-2102. PubMed ID: 32394215
[No Abstract] [Full Text] [Related]
19. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
